Literature DB >> 16924115

Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins.

Tomasz Sitar1, Grzegorz M Popowicz, Igor Siwanowicz, Robert Huber, Tad A Holak.   

Abstract

Insulin-like growth factor-binding proteins (IGFBPs) control bioavailability, activity, and distribution of insulin-like growth factor (IGF)1 and -2 through high-affinity IGFBP/IGF complexes. IGF-binding sites are found on N- and C-terminal fragments of IGFBPs, the two conserved domains of IGFBPs. The relative contributions of these domains to IGFBP/IGF complexation has been difficult to analyze, in part, because of the lack of appropriate three-dimensional structures. To analyze the effects of N- and C-terminal domain interactions, we determined several x-ray structures: first, of a ternary complex of N- and C-terminal domain fragments of IGFBP4 and IGF1 and second, of a "hybrid" ternary complex using the C-terminal domain fragment of IGFBP1 instead of IGFBP4. We also solved the binary complex of the N-terminal domains of IGFBP4 and IGF1, again to analyze C- and N-terminal domain interactions by comparison with the ternary complexes. The structures reveal the mechanisms of IGF signaling regulation via IGFBP binding. This finding supports research into the design of IGFBP variants as therapeutic IGF inhibitors for diseases of IGF disregulation. In IGFBP4, residues 1-38 form a rigid disulphide bond ladder-like structure, and the first five N-terminal residues bind to IGF and partially mask IGF residues responsible for the type 1 IGF receptor binding. A high-affinity IGF1-binding site is located in a globular structure between residues 39 and 82. Although the C-terminal domains do not form stable binary complexes with either IGF1 or the N-terminal domain of IGFBP4, in the ternary complex, the C-terminal domain contacts both and contributes to blocking of the IGF1 receptor-binding region of IGF1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924115      PMCID: PMC1551901          DOI: 10.1073/pnas.0605652103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Use of mutagenesis to probe IGF-binding protein structure/function relationships.

Authors:  D R Clemmons
Journal:  Endocr Rev       Date:  2001-12       Impact factor: 19.871

2.  BIAcore analysis of bovine insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site determinants in both the amino- and carboxyl-terminal domains.

Authors:  F E Carrick; B E Forbes; J C Wallace
Journal:  J Biol Chem       Date:  2001-05-16       Impact factor: 5.157

3.  The interaction of insulin-like growth factor-I with the N-terminal domain of IGFBP-5.

Authors:  W Zesławski; H G Beisel; M Kamionka; W Kalus; R A Engh; R Huber; K Lang; T A Holak
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

4.  Diversity and evolution of the thyroglobulin type-1 domain superfamily.

Authors:  Marko Novinec; Dusan Kordis; Vito Turk; Brigita Lenarcic
Journal:  Mol Biol Evol       Date:  2005-12-20       Impact factor: 16.240

Review 5.  IGF-binding proteins--the pieces are falling into place.

Authors:  Leon A Bach; Stephen J Headey; Raymond S Norton
Journal:  Trends Endocrinol Metab       Date:  2005-07       Impact factor: 12.015

6.  Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to insulin-like growth factor-1 binding.

Authors:  Megan M Kibbey; Mark J Jameson; Erin M Eaton; Steven A Rosenzweig
Journal:  Mol Pharmacol       Date:  2005-11-23       Impact factor: 4.436

7.  Interaction of insulin-like growth factor (IGF)-I and -II with IGF binding protein-2: mapping the binding surfaces by nuclear magnetic resonance.

Authors:  F E Carrick; M G Hinds; K A McNeil; J C Wallace; B E Forbes; R S Norton
Journal:  J Mol Endocrinol       Date:  2005-06       Impact factor: 5.098

8.  Ligand-binding characteristics of recombinant amino- and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3.

Authors:  M Galanis; S M Firth; J Bond; A Nathanielsz; A A Kortt; P J Hudson; R C Baxter
Journal:  J Endocrinol       Date:  2001-04       Impact factor: 4.286

9.  Cumulative mutagenesis of the basic residues in the 201-218 region of insulin-like growth factor (IGF)-binding protein-5 results in progressive loss of both IGF-I binding and inhibition of IGF-I biological action.

Authors:  Gordon J Allan; Elizabeth Tonner; Malgorzata Szymanowska; John H Shand; Sharon M Kelly; Kirsten Phillips; Roger A Clegg; Iain F Gow; James Beattie; David J Flint
Journal:  Endocrinology       Date:  2005-09-29       Impact factor: 4.736

Review 10.  Targeting insulin-like growth factor pathways.

Authors:  D Yee
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640

View more
  52 in total

1.  Molecular identification of grass carp igfbp2 and the effect of glucose, insulin, and glucagon on igfbp2 mRNA expression.

Authors:  Guokun Yang; Wenli Zhao; Chaobin Qin; Liping Yang; Xiaolin Meng; Ronghua Lu; Xiao Yan; Xianglin Cao; Yanmin Zhang; Guoxing Nie
Journal:  Fish Physiol Biochem       Date:  2020-04-23       Impact factor: 2.794

2.  First structural glimpse of CCN3 and CCN5 multifunctional signaling regulators elucidated by small angle x-ray scattering.

Authors:  Kenneth P Holbourn; Marc Malfois; K Ravi Acharya
Journal:  J Biol Chem       Date:  2011-05-04       Impact factor: 5.157

Review 3.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

4.  The role and regulation of IGFBP-1 phosphorylation in fetal growth restriction.

Authors:  Madhulika B Gupta
Journal:  J Cell Commun Signal       Date:  2015-02-15       Impact factor: 5.782

5.  Defining the disulfide bonds of insulin-like growth factor-binding protein-5 by tandem mass spectrometry with electron transfer dissociation and collision-induced dissociation.

Authors:  Mahta Nili; Aditi Mukherjee; Ujwal Shinde; Larry David; Peter Rotwein
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

6.  Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.

Authors:  Ian Damerill; Kyle K Biggar; Majida Abu Shehab; Shawn Shun-Cheng Li; Thomas Jansson; Madhulika B Gupta
Journal:  Mol Endocrinol       Date:  2015-12-29

7.  CCN1 mutation is associated with atrial septal defect.

Authors:  Andreas Perrot; Katharina R Schmitt; Eva-Maria G Roth; Brigitte Stiller; Maximilian G Posch; Edmund N L Browne; Christian Timmann; Rolf D Horstmann; Felix Berger; Cemil Özcelik
Journal:  Pediatr Cardiol       Date:  2014-08-19       Impact factor: 1.655

8.  Stanniocalcin-2 inhibits mammalian growth by proteolytic inhibition of the insulin-like growth factor axis.

Authors:  Malene R Jepsen; Søren Kløverpris; Jakob H Mikkelsen; Josefine H Pedersen; Ernst-Martin Füchtbauer; Lisbeth S Laursen; Claus Oxvig
Journal:  J Biol Chem       Date:  2014-12-22       Impact factor: 5.157

9.  Age-related macular degeneration-associated silent polymorphisms in HtrA1 impair its ability to antagonize insulin-like growth factor 1.

Authors:  Sarah Melissa P Jacobo; Margaret M Deangelis; Ivana K Kim; Andrius Kazlauskas
Journal:  Mol Cell Biol       Date:  2013-03-11       Impact factor: 4.272

Review 10.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.